








. That's going to seriously impact their return on investment and make marketing their treatment difficult.Perhaps they'll get a better responder rate when they look at all their phase II data. But if they don't, i'm not convinced they can justify going ahead with a costly phase III.
Lets keep our fingers crossed and hope for the best. Right now, i'm betting on Histogen. But, lets see some data...feel like we've been in a data drought since replicel sh*t the bed.

Leave a comment: